Обоснование коррекции иммунологических нарушений у онкогинекологических пациенток в процессе цикловой химиотерапии

Were studied the mechanisms of immunological disorders in 37 women with ovarian cancer in the process of cycle chemotherapy (CT). It is shown that the inclusion of OT imunofan (treatment group) has improved the immunological reactivity, contributed to increasing the total volume of specific therapy. Completeness of cycle chemotherapy in the study group was 94.7%, in the comparison group 72.2%.